Advertising disclosure: we may earn a commission when you buy through links on this site. How we make money

HomeTrials › NCT06962280

Obesity & weight · Phase 3 · Active, not recruiting

A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

NCT06962280 · Sponsor: Eli Lilly and Company

What this trial means for you

This study is active, not recruiting — it is not currently taking new participants, but its results may matter for treatments you're considering. It's studying Tirzepatide, Placebo for type 1 diabetes, obesity, overweight.

Who can joinAll sexes, 18 Years and older
Healthy volunteersNo — diagnosis required
What you'd takeTirzepatide, Placebo
Study length~18 months overall
Planned participants465
TypeInterventional (you receive treatment)

What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.

The study, in the sponsor's words

The main purpose of this study is to find out how well and how safely tirzepatide works long-term in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 20 months.

Can you join? The exact criteria

Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.

Full eligibility criteria (for you and your doctor)

Inclusion Criteria: * Have type 1 diabetes and on insulin treatment for at least one year prior to screening * Have an HbA1c value of 7.0% to 10.5% inclusive, at screening * Have a body mass index (BMI) of ≥25 kilograms per square meter (kg/m2) at screening * Are of stable weight for at least 90 days prior to screening and agree to not start an intensive diet or exercise program during the study Exclusion Criteria: * Have experienced two or more events requiring hospitalization due to poor glucose control (hyperglycemia or (diabetic ketoacidosis (DKA)) during the period of 180 days prior to screening and until randomization. * Have experienced one or more events of severe hypoglycemia during the period of 90 days prior to screening and until randomization. * Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema * Have had chronic or acute pancreatitis * Have used any weight loss drugs or alternative remedies, including herbal or nutritional supplements, within 90 days prior to screening

Study sites by state

California

  • Kaiser Permanente Bonita Medical Offices — Bonita
  • AMCR Institute — Escondido
  • Mary & Dick Allen Diabetes Center — Newport Beach
  • University Clinical Investigators, Inc. — Tustin

Colorado

  • University of Colorado Anschutz Medical Campus — Aurora

Florida

  • Metabolic Research Institute, Inc. — West Palm Beach

Iowa

  • Iowa Diabetes and Endocrinology Research Center — West Des Moines

Minnesota

  • HealthPartners Institute dba International Diabetes Center — Minneapolis

Missouri

  • Clinical Research Professionals — Chesterfield
  • Clinvest Headlands Llc — Springfield

Nevada

  • Las Vegas Endocrinology — Henderson

North Carolina

  • University of North Carolina Medical Center — Chapel Hill

Texas

  • Velocity Clinical Research, Dallas — Dallas
  • Juno Research — Houston
  • Southern Endocrinology Associates — Mesquite
  • Texas Diabetes & Endocrinology, P.A. — Round Rock
  • San Antonio Clinical Trials — San Antonio
  • Texas Valley Clinical Research — Weslaco

View the official record on ClinicalTrials.gov →

Verify before you act. Medical disclaimer: content on this site is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs; always consult a licensed healthcare provider about eligibility, risks, and benefits. Trial details and enrollment status change frequently — always verify on the official registry and talk to your own clinician before contacting a study site. This page was generated from registry data and is not affiliated with the study sponsor.

Follow this trial

Get an email when our monthly digest covers enrollment changes and results for trials like this one.

Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in .env to activate this form.)

Keep researching on StudyBackedHealth